Fulgent Genetics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3596641098
USD
28.30
-0.1 (-0.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Fulgent Genetics, Inc. stock-summary
stock-summary
Fulgent Genetics, Inc.
Pharmaceuticals & Biotechnology
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
Company Coordinates stock-summary
Company Details
4978 Santa Anita Ave Ste 205 , TEMPLE CITY CA : 91780-3600
stock-summary
Tel: 1 626 35005371 415 2175865
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 52 Schemes (27.6%)

Foreign Institutions

Held by 92 Foreign Institutions (7.27%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ming Hsieh
Chairman of the Board, President, Chief Executive Officer
Mr. John Bolger
Independent Director
Ms. Linda Marsh
Independent Director
Dr. Yun Yen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
82 Million
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 682 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.26

stock-summary
Return on Equity

-2.87%

stock-summary
Price to Book

0.61